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Human immunodeficiency virus type 2 (HIV-2) infection is a significant public health problem in West Africa and has been reported in other countries with socioeconomic ties to the region \[[@CR1]\]. Dual HIV-1/HIV-2 infection also occurs in areas where the viruses co-circulate \[[@CR2]-[@CR6]\]. Historically, clinical outcomes of antiretroviral therapy in HIV-2 and HIV-1/HIV-2 dually positive patients have been poor, with high rates of immuno-virologic failure and emergent multidrug resistance \[[@CR7]-[@CR11]\]. Newer classes of antiretrovirals (ARV) with anti--HIV-2 activity could represent substantial improvements to the current therapeutic picture \[[@CR12],[@CR13]\].

A growing body of evidence suggests that integrase strand transfer inhibitors (INSTI) might be particularly useful for HIV-2 treatment. Raltegravir and elvitegravir are both potent inhibitors of HIV-2 replication in culture \[[@CR14]-[@CR18]\], and case reports and small case series (primarily involving ARV-experienced individuals) indicate that raltegravir and elvitegravir can reduce HIV-2 viral loads when combined with other suppressive ARV \[[@CR19]-[@CR32]\]. As with HIV-1, changes at integrase residues Y143, Q148 or N155, together with other secondary replacements in the integrase protein (*i.e.*, E92Q, T97A, G140S, and possibly others), confer resistance to raltegravir in HIV-2 \[[@CR26],[@CR28]-[@CR35]\]. The emergence of resistance to elvitegravir has not yet been reported in HIV-2-infected individuals but will likely involve these same three pathways based on studies of HIV-1 \[[@CR36]-[@CR50]\] and the extensive cross-resistance seen between raltegravir and elvitegravir in HIV-2 in culture \[[@CR15],[@CR17]\]. Clinical trials of raltegravir- and elvitegravir-containing regimens for first-line HIV-2 treatment are now underway and are expected to yield data within the next few years (NCT01605890, NCT02150993, NCT02180438).

A third strand transfer inhibitor, dolutegravir, was recently approved by the United States Food and Drug Administration (FDA) for use in both INSTI-naïve and INSTI-experienced HIV-1 patients. Although dolutegravir has been extensively evaluated for HIV-1 treatment, few studies have examined its potential use in HIV-2--infected individuals. Charpentier and colleagues reported that HIV-2~ROD,~ HIV-1~BRU~, and eight HIV-2 isolates from INSTI-naïve patients were comparably susceptible to dolutegravir in spreading infections of peripheral blood mononuclear cells (PBMC) (EC~50~ = 0.2--4 nM) and that three HIV-2 isolates from raltegravir-treated individuals with consensus integrase genotypes G140S + Q148R (group A), G140T + Q148R + N155H (group A), and T97A + Y143C (group H) were 63-, 9-, and 5-fold resistant to dolutegravir, respectively, in PBMC \[[@CR51]\]. In addition, the manufacturer of dolutegravir (ViiV Healthcare) reported that EC~50~ values against three clinical isolates of HIV-2 ranged from 0.09 nM to 0.61 nM in PBMC assays, and that combinations of substitutions A153G + N155H + S163G and E92Q + T97A + N155H + S163D in HIV-2 integrase conferred 4-fold decreases in dolutegravir susceptibility, while E92Q + N155H and G140S + Q148R resulted in 8.5-fold and 17-fold decreases, respectively \[[@CR52]\].

The ability of dolutegravir to inhibit strains resistant to other INSTI is of particular importance--in HIV-1, mutations Q148H/K/R, together with secondary changes in the integrase protein, confer resistance to dolutegravir in cell culture \[[@CR38],[@CR47],[@CR53]-[@CR55]\], and other mutations associated with diminished in vitro susceptibility to dolutegravir have been reported \[[@CR56]-[@CR61]\]. In contrast, dolutegravir is fully active against HIV-1 variants bearing Y143 or N155 mutations (with or without secondary changes) in both single-cycle and spreading infection assays \[[@CR38],[@CR47],[@CR53]-[@CR55]\], although it should be noted that Y143 and N155 mutants have been observed in raltegravir-experienced patients who subsequently failed dolutegravir-based regimens \[[@CR62],[@CR63]\]. In the VIKING-3 trial, dolutegravir response rates (\<50 HIV-1 RNA copies/ml at week 24) declined from 79% (n = 100/126) for patients without Q148 mutations at baseline (including those with N155H, Y143C/H/R, T66A, E92Q, or historical evidence of INSTI resistance), to 58% (21/36) for patients with Q148 plus one additional secondary mutation, to 24% (5/21) for those with Q148 plus two or more secondary mutations \[[@CR64]\]. Importantly, drug resistance testing is not widely available in West Africa, and thus, dolutegravir usage in many HIV-2--infected patients, including INSTI-experienced individuals, will depend on an algorithmic approach to treatment. To date, there are only two reports of dolutegravir treatment for HIV-2 infection (\[[@CR65],[@CR66]\]; n = 2 and 13 patients, respectively), with limited duration of follow-up.

In the present study, we examined the activity of dolutegravir against wild-type and INSTI-resistant HIV-2 strains using an indicator cell assay that restricts viral replication to a single cycle \[[@CR15]\]. This methodology enables a direct comparison of HIV-1 and HIV-2 drug susceptibility while avoiding potential confounders such as differences in replication rates, infectivity, cytopathic potential and cell-to-cell spread.

We initially compared the dolutegravir sensitivities of viruses derived from two prototypic full-length molecular clones: pNL4-3 (HIV-1 group M, subtype B) and pROD9 (HIV-2 group A). In head-to-head single-cycle assays, these two strains showed nearly identical dose-response profiles (Figure [1](#Fig1){ref-type="fig"}A). Over multiple assays runs, the mean EC~50~ values for dolutegravir (± standard deviation) were 1.5 ± 0.6 nM for HIV-1~NL4-3~ and 2.3 ± 0.7 nM for HIV-2~ROD9~ (n = 14 and 24 determinations, respectively). Dolutegravir was 3.6-fold more potent than raltegravir and 9.1-fold more potent than elvitegravir against HIV-2~ROD9~ (Figure [1](#Fig1){ref-type="fig"}B). Other isolates from ARV-naïve individuals displayed levels of dolutegravir sensitivity comparable to HIV-1~NL4-3~ and HIV-2~ROD9~ (Figure [1](#Fig1){ref-type="fig"}C). The aggregate EC~50~ values for HIV-1, HIV-2 group A, and HIV-2 group B were 1.3 ± 0.2 nM, 1.9 ± 0.5 nM, and 2.6 ± 0.9 nM, respectively. When subjected to a one-way ANOVA, only the comparison between HIV-1 and HIV-2 group B reached statistical significance (p \< 0.05); this modest difference was attributable to the slightly higher EC~50~ for HIV-2~EHO~ (3.6 ± 1.9 nM) (Figure [1](#Fig1){ref-type="fig"}C). Notably, HIV-2~EHO~ integrase contains a glutamate at position 146, whereas other HIV-2 isolates (as well as HIV-1) encode glutamine at this site \[[@CR67],[@CR68]\]. Substitutions at Q146 have been observed in HIV-1 following in vitro selections with elvitegravir and other, investigational INSTI \[[@CR18],[@CR69],[@CR70]\]. To our knowledge, Q146 mutations have not been observed in HIV-2 variants selected in culture, nor have they been reported in HIV-2 patients treated with INSTI-based regimens.Figure 1**Susceptibility of wild-type HIV-1 and HIV-2 isolates to dolutegravir in the single-cycle assay. (A)** Representative dose-response profiles for HIV-1~NL4-3~ and HIV-2~ROD9~. Virus stocks were generated by transient transfection of chloroquine-treated 293T/17 cultures with plasmids pNL4-3 and pROD9, respectively. Dolutegravir was obtained from Selleck Chemicals, Inc. Titers are expressed as the percentage of no-drug (solvent-only) controls and are the means of two independent cultures at each drug concentration. Curve fits were generated using the sigmoid dose-response function of Prism version 6.0 (GraphPad Software, Inc.). **(B)** Comparison of the activity of dolutegravir (DTG), raltegravir (RAL), and elvitegravir (EVG) against wild-type HIV-2~ROD9~. Values for RAL and EVG include data from two previously-published studies of HIV-2 from our group \[[@CR14],[@CR15]\] plus additional determinations; all data were obtained using the single-cycle assay. Bars indicate mean 50% effective concentrations (EC~50~); the number of independent determinations (n) for each strain is shown below the x-axis. P values were obtained via analysis of variance (ANOVA) of log~10~-transformed EC~50~ values with Tukey's post test (Prism v6.0). No cytotoxic effects were observed in dolutegravir-treated MAGIC-5A cultures at concentrations as high as 10,000 nM. **(C)** Activity of dolutegravir against wild-type HIV-1 and HIV-2 isolates. Group/subtype designations are shown in parentheses. HIV-1~NL4-3~ and HIV-2~ROD9~ were generated as in panel A. HIV-2~EHO~ was kindly provided by Jan McClure (University of Washington). The remaining isolates were obtained from the National Institutes of Health AIDS Reagent Program ([www.aidsreagent.org](http://www.aidsreagent.org)). \*, significantly greater than HIV-2~ROD9~, HIV-2~MVP15132~, HIV-2~CBL20~, and all HIV-1 isolates listed (p \< 0.05, ANOVA with Tukey's post test). In all panels, error bars indicate standard deviations.

To examine potential resistance pathways in HIV-2, we tested the activity of dolutegravir against a panel of site-directed mutants of HIV-2~ROD9~ using the single-cycle assay. These variants contained amino acid replacements in the integrase protein that are associated with raltegravir and elvitegravir treatment; their phenotypes with respect to raltegravir and elvitegravir susceptibility have been reported elsewhere \[[@CR14],[@CR15]\]. Single amino acid changes T97A, G140S, Q148H and N155H had no significant effect on dolutegravir sensitivity (p \> 0.05, ANOVA; Figure [2](#Fig2){ref-type="fig"}A). In contrast, mutants E92Q, Y143C, E92Q + Y143C, Q148K, and Q148R were resistant to dolutegravir, with EC~50~ values 2.3--9.3-fold greater than that of the parental strain (Figure [2](#Fig2){ref-type="fig"}A), and variants E92Q + N155H, T97A + N155H and G140S + Q148R exhibited 11--33-fold resistance to the drug (p \< 0.05, ANOVA; Figure [2](#Fig2){ref-type="fig"}A and B). In experiments with T97A + Y143C HIV-2~ROD9~, dolutegravir concentrations as high as 10 μM failed to reduce viral replication by 50% (Figure [2](#Fig2){ref-type="fig"}A and C; EC~50~ \> 10 μM), although modest dose-dependent inhibition was apparent at doses ≥100 nM (Figure [2](#Fig2){ref-type="fig"}C). Altogether, nine of the 13 HIV-2 integrase mutants tested were resistant to dolutegravir in the single-cycle assay (Figure [2](#Fig2){ref-type="fig"}A).Figure 2**Antiviral activity of dolutegravir against site-directed mutants of HIV-1 and HIV-2 integrase in the single-cycle assay. (A)** EC~50~ values for wild-type (WT) HIV-2~ROD9~ and HIV-2~ROD9~ integrase mutants generated in the full-length pROD9 molecular clone. Shaded bars indicate strains that are significantly different from wild-type (p \< 0.05, ANOVA of log~10~-transformed EC~50~ values with Tukey's post test; Prism v6.0). The number of independent determinations (n) for each strain is shown below the x-axis. **(B)** and **(C)** Representative dose-response profiles for WT, E92Q + N155H, G140S + Q148R and T97A + Y143C HIV-2~ROD9~. Data are the means of three independent cultures at each dose of dolutegravir (DTG). Curve fits were generated as described in Figure [1](#Fig1){ref-type="fig"}A. **(D)** Comparative analysis of equivalent site-directed mutants of HIV-1 and HIV-2 integrase. Each point is the result of a single dose-response assay performed as described in Figure [1](#Fig1){ref-type="fig"}A. Horizontal bars indicate the mean EC~50~ values for each strain. Red arrows and text indicate fold increases in the mean EC~50~ values for HIV-2 relative to HIV-1. ANOVA results for these data are described in the main text. In all panels, error bars represent standard deviations.

We also evaluated the dolutegravir sensitivities of E92Q + N155H, T97A + Y143C, and G140S + Q148R HIV-2~ROD9~ in three-day spreading infections of immortalized T cells (CEM-ss). These assays were preformed as previously described for the MT-2 T cell line \[[@CR14]\]. The resultant EC~50~ values for the parental strain, E92Q + N115H, and G140S + Q148R were 0.24, 2.1 and 73 nM, respectively, indicating 8.8-fold resistance to dolutegravir for E92Q + N115H and 300-fold resistance for G140S + Q148R. Despite repeated attempts using high multiplicities of infection (≥0.1) and prolonged incubation times (up to seven days), CEM-ss cultures inoculated with T97A + Y143C HIV-2~ROD9~ failed to produce detectable levels of infectious virus, indicating a severe fitness defect. This result is consistent with the poor replication capacity previously reported for T97A + Y143C HIV-2~ROD9~ \[[@CR15]\].

Lastly, we performed a head-to-head comparison of the phenotypes conferred by E92Q + N155H, G140S + Q148R, and T97A + Y143C in HIV-1~NL4-3~ and HIV-2~ROD9~ in the single-cycle assay. G140S + Q148R resulted in slight resistance to dolutegravir in HIV-1~NL4-3~ (3.5-fold; p \<0.01, ANOVA), whereas E92Q + N155H and T97A + Y143C had no statistically significant effect in the HIV-1~NL4-3~ background (Figure [2](#Fig2){ref-type="fig"}D). These data are entirely consistent with previous studies of HIV-1 \[[@CR38],[@CR47],[@CR53],[@CR54]\]. In contrast, HIV-2~ROD9~ mutants E92Q + N155H, G140S + Q148R, and T97A + Y143C were all resistant to dolutegravir (p \< 0.0001, ANOVA) and showed EC~50~ values 4-, 21- and \>5000-fold greater than those seen for equivalent mutants of HIV-1~NL4-3~, respectively (Figure [2](#Fig2){ref-type="fig"}D). EC~50~ and fold change values for all HIV-1~NL4-3~ and HIV-2~ROD9~ integrase mutants tested in this study, together with the corresponding EC~50~ values for the parental wild-type clones, are compiled in Table [1](#Tab1){ref-type="table"}.Table 1**Compilation of EC** ~**50**~ **and fold change values for site-directed mutants of HIV-2** ~**ROD9**~ **and HIV-1** ~**NL4-3**~ **integraseHIV TypeStrainEC** ~**50**~ **for DTG (nM)** ^**a**^**n** ^**b**^**Fold Change** ^**c**^HIV-2Wild-type2.3 ± 0.724E92Q**7.7 ± 1.2**33T97A3.2 ± 0.831G140S3.2 ± 0.831Y143C**7.7 ± 2.2**33Q148H3.5 ± 1.441Q148K**23 ± 10**410Q148R**5.7 ± 2.1**42N155H5.0 ± 2.432E92Q + Y143C**15 ± 10**56T97A + Y143C**\>10000**13\>5000G140S + Q148R**108 ± 54**746E92Q + N155H**25 ± 17**710T97A + N155H**27 ± 13**312HIV-1Wild-type1.5 ± 0.614T97A + Y143C1.5 ± 0.441G140S + Q148R**6.8 ± 2.7**44E92Q + N155H**3.6 ± 0.7**42^a^50% effective concentration of dolutegravir (DTG) as measured in the MAGIC-5A single-cycle assay. Values were compiled from the data used to generate Figures [2](#Fig2){ref-type="fig"}A and [2](#Fig2){ref-type="fig"}D and are expressed as means ± standard deviations. Numbers shown in bold type are significantly greater than the values for the corresponding wild-type strains (p \< 0.05; ANOVA of log~10~-transformed EC~50~ values with Tukey's post-test; performed in Prism version 6.0, GraphPad Software, Inc.).^b^Number of independent determinations for each strain.^c^Fold change in EC~50~ relative to the corresponding wild-type strain.

Taken together, our results indicate that prototypic HIV-1 and HIV-2 strains, as well as HIV-1 and HIV-2 isolates from INSTI-naïve individuals, are comparably sensitive to dolutegravir in a single cycle of viral replication in MAGIC-5A indicator cells (Figure [1](#Fig1){ref-type="fig"}). These findings complement previous data from spreading infections of PBMC \[[@CR51]\]--using a different methodology and target cell type--and suggest that dolutegravir would be an appropriate treatment choice for INSTI-naïve HIV-2 patients when combined with other HIV-2--active ARV. We also report the effects of raltegravir-associated mutations on dolutegravir susceptibility using site-directed mutagenesis of genetically-defined HIV-1 and HIV-2 molecular clones (pNL4-3 and pROD9, respectively). Our analysis shows that equivalent amino acid changes in the integrase proteins of HIV-1 and HIV-2 can have differing effects on dolutegravir susceptibility (Figure [2](#Fig2){ref-type="fig"}D) and that, in HIV-2~ROD9~, integrase changes Q148K, T97A + Y143C, E92Q + N155H, T97A + N155H, and G140S + Q148R confer moderate to high levels of dolutegravir resistance (≥10-fold; Figure [2](#Fig2){ref-type="fig"}A--C and Table [1](#Tab1){ref-type="table"}). We cannot exclude the possibility that the resistance levels observed in our site-directed HIV-2 mutants are specific to the ROD9 molecular clone, as the genetic context within integrase can have a substantial impact on the phenotypic expression of INSTI resistance \[[@CR71],[@CR72]\]. For example, in the aforementioned study by Charpentier et al. \[[@CR51]\], a group H HIV-2 isolate with T97A + Y143C was only 5-fold resistant to dolutegravir (this isolate differs from HIV-2~ROD9~ at 24 of 293 amino acid sites in the integrase protein). In addition, the roles of novel INSTI-associated changes (i.e, H51Y, G118R, F121Y, E138A/K, and R263K; \[[@CR26],[@CR34],[@CR57]-[@CR61],[@CR63],[@CR73]\]) remain to be determined in HIV-2, and the level of dolutegravir resistance in vitro that correlates with virologic failure in HIV-2--infected patients is unknown. Nonetheless, our findings suggest that, relative to HIV-1, a broader array of amino acid changes in HIV-2 integrase might facilitate cross-resistance between dolutegravir and other INSTI. Phenotypic drug resistance testing of HIV-2 isolates from raltegravir- and elvitegravir-treated patients should be performed as these drugs become more widely available in West Africa, and studies of dolutegravir-based regimens should be conducted in HIV-2--infected individuals, including patients previously treated with other INSTI.
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